EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities

Ana Bogut, Bojan Stojanovic iD, Marina Jovanovic, Milica Dimitrijevic Stojanovic, Nevena Gajovic, Bojana S Stojanovic, Goran Balovic, Milan Jovanovic, Aleksandar Lazovic iD, Milos Mirovic, Milena Jurisevic, Ivan Jovanovic iD und 1 weitere

International Journal of Molecular Sciences · 24.10.2023 · 24 (21) · 15500

DOI: 10.3390/ijms242115500 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.10.2023. Verfasst von Ana Bogut und 12 weiteren Autor:innen. Beteiligte Einrichtung: City Medical Emergency Department, 11000 Belgrade, Serbia. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Galectin 1, Pancreatic Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia, the Faculty of Medical Sciences at the University of Kragujevac, Serbia, the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging malignancies to treat, with a complex interplay of molecular pathways contributing to its aggressive nature. Galectin-1 (Gal-1), a member of the galectin family, has emerged as a pivotal player in the PDAC microenvironment, influencing various aspects from tumor growth and angiogenesis to immune modulation. This review provides a comprehensive overview of the multifaceted role of Galectin-1 in PDAC. We delve into its contributions to tumor stroma remodeling, angiogenesis, metabolic reprogramming, and potential implications for therapeutic interventions. The challenges associated with targeting Gal-1 are discussed, given its pleiotropic functions and complexities in different cellular conditions. Additionally, the promising prospects of Gal-1 inhibition, including the utilization of nanotechnology and theranostics, are highlighted. By integrating recent findings and shedding light on the intricacies of Gal-1’s involvement in PDAC, this review aims to provide insights that could guide future research and therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalGalectin 1Pancreatic NeoplasmsHumansImmune EvasionTumor Microenvironment

Stichwörter der Autor:innen

Galectin-1angiogenesisimmune modulationpancreatic ductal adenocarcinomatumor microenvironment

Substanzen

Galectin 1

Autor:innen und Institutionen

  • City Medical Emergency Department, 11000 Belgrade, Serbia.
  • Department of Surgery, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Department of General Surgery, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.
  • Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

ORCID-Profile: Bojan Stojanovic, Aleksandar Lazovic, Ivan Jovanovic

Förderung

  • Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
  • the Faculty of Medical Sciences at the University of Kragujevac, Serbia
  • the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia

Zitieren

APA

Bogut, A., Stojanovic, B., Jovanovic, M., Dimitrijevic Stojanovic, M., Gajovic, N., Stojanovic, B. S., Balovic, G., Jovanovic, M., Lazovic, A., Mirovic, M., Jurisevic, M., Jovanovic, I., & Mladenovic, V. (2023). Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities. International Journal of Molecular Sciences, 24(21), 15500. https://doi.org/10.3390/ijms242115500

Vancouver

Bogut A, Stojanovic B, Jovanovic M, Dimitrijevic Stojanovic M, Gajovic N, Stojanovic BS, et al. Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities. International Journal of Molecular Sciences. 2023;24(21):15500. doi:10.3390/ijms242115500

BibTeX
@article{Bogut2023,
  author = {Bogut, Ana and Stojanovic, Bojan and Jovanovic, Marina and Dimitrijevic Stojanovic, Milica and Gajovic, Nevena and Stojanovic, Bojana S and Balovic, Goran and Jovanovic, Milan and Lazovic, Aleksandar and Mirovic, Milos and Jurisevic, Milena and Jovanovic, Ivan and Mladenovic, Violeta},
  title = {Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {21},
  pages = {15500},
  doi = {10.3390/ijms242115500}
}
Kostenlos starten →